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Abstract
The nuclear factor erythroid 2-related factor 2 (Nrf2) is considered as a master cytoprotective factor regulating the
expression of genes encoding anti-oxidant, anti-inflammatory, and detoxifying proteins. The role of Nrf2 in the
pathophysiology of skeletal muscles has been evaluated in different experimental models, however, due to
inconsistent data, we aimed to investigate how Nrf2 transcriptional deficiency (Nrf2tKO) affects muscle functions
both in an acute and chronic injury. The acute muscle damage was induced in mice of two genotypes—WT and
Nrf2tKO mice by cardiotoxin (CTX) injection. To investigate the role of Nrf2 in chronic muscle pathology, mdx mice
that share genetic, biochemical, and histopathological features with Duchenne muscular dystrophy (DMD) were
crossed with mice lacking transcriptionally active Nrf2 and double knockouts (mdx/Nrf2tKO) were generated. To
worsen the dystrophic phenotype, the analysis of disease pathology was also performed in aggravated conditions,
by applying a long-term treadmill test. We have observed slightly increased muscle damage in Nrf2tKO mice after
CTX injection. Nevertheless, transcriptional ablation of Nrf2 in mdx mice did not significantly aggravate the most
deleterious, pathological hallmarks of DMD related to degeneration, inflammation, fibrotic scar formation,
angiogenesis, and the number and proliferation of satellite cells in non-exercised conditions. On the other hand,
upon chronic exercises, the degeneration and inflammatory infiltration of the gastrocnemius muscle, but not the
diaphragm, turned to be increased in Nrf2tKOmdx in comparison to mdx mice. In conclusion, the lack of
transcriptionally active Nrf2 influences moderately muscle pathology in acute CTX-induced muscle injury and
chronic DMD mouse model, without affecting muscle functionality. Hence, in general, we demonstrated that the
deficiency of Nrf2 transcriptional activity has no profound impact on muscle pathology in various models of muscle
injury.
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Background
Duchenne muscular dystrophy (DMD) is the most com-
mon form of muscular dystrophies [1], which affects one
in 5000-6000 male births [2]. DMD is the lethal X-
chromosome linked recessive genetic neuromuscular
disorder, caused by mutations in the gene encoding dys-
trophin [1]. Dystrophin deficiency leads to progressive
muscle weakness, severe muscular atrophy, cardiomyop-
athy, and respiratory impairments, the two latter being
the leading causes of mortality among patients with
DMD [2]. Dystrophin, a cytoskeletal protein, is a major
structural element of the dystrophin-glycoprotein com-
plex (DGC), which is responsible for maintaining cellular
integrity by linking the sarcolemmal and actin cytoskel-
eton to the extracellular matrix component laminin [3].
The loss of dystrophin disrupts the complex resulting in
sarcolemmal instability that makes cells more susceptible
to damage and leads to necrosis of muscle fibers [3].
Consequently, it results in the activation of the innate
immune system, excessive inflammatory response, and
increased oxidative stress [4].
In the early stage of the inflammatory response, mus-
cles are infiltrated by neutrophils and pro-inflammatory,
phagocytic M1-like macrophages which are a rich source
of Th1 cytokines, that promote the activation and
chemotaxis of myeloid cells to damaged tissue. More-
over, cytokines affect proliferation, migration, and differ-
entiation of muscle satellite cells (SCs), progenitors of
mature skeletal muscle. Subsequently, the recruitment of
anti-inflammatory and pro-regenerative subpopulation
of M2-like macrophages is observed [5]. In addition to
macrophages and neutrophils, other inflammatory cells,
including T-lymphocytes (cytotoxic, helper) may con-
tribute to disease progression [6].
Subsequently, the injury leads to muscle regeneration,
a process that depends on activation and proliferation of
SCs and their differentiation into myotubes and later on
regenerating myofibres that are centrally nucleated and
exhibit expression of embryonic myosin heavy chain
(eMyHC) isoform. Eventually, in chronic injury, the con-
tinuous cycles of myofiber degeneration and regener-
ation induce exhaustion of SCs and substitution of
muscle with fibroadipose tissue [4]. Additionally, oxida-
tive stress with elevated production of reactive oxygen
species (ROS) has been proposed as important contribu-
tors in the pathogenesis of the DMD in humans [7] and
mdx mice (murine model of DMD) [8].
Recently, we have shown that expression of heme
oxygenase-1 (HO-1, encoded by Hmox1), anti-
inflammatory, and cytoprotective enzyme, is strongly el-
evated in muscles of mdx mice and muscle biopsies of
DMD patients [9]. Genetic loss of HO-1 not only exac-
erbates dystrophic phenotype and inflammation in mdx
mice [9] but also aggravates skeletal muscle injury in
acute muscle damage model, i.e., following cardiotoxin
(CTX) injection [10]. Expression of Hmox1 is regulated,
among others, by the redox-sensitive nuclear factor
erythroid 2-related factor 2 (Nrf2, encoded by Nfe2l2
gene) belonging to Cap “n” collar (Cnc)-bZIP (basic leu-
cine zipper) family of transcription factors [11]. Nrf2
plays a cytoprotective role as a master regulator of genes
encoding oxidative stress response and phase II detoxify-
ing proteins by interacting with the anti-oxidant re-
sponse element (ARE) sequence. Under normal
circumstances, Nrf2 is sequestered in the cytoplasm by
Kelch-like ECH-associating protein 1 (Keap1) through
the Nrf2-Keap1 complex, which suppresses Nrf2 activity
by targeting it for ubiquitination and degradation. In
stressful conditions, Nrf2 dissociates from Keap1, trans-
locates into the nucleus, and induces the expression of
target genes [12]. The role of Nrf2 in skeletal muscle
aging and adaptations to exercise through the regulation
of mitochondrial function, maintaining the cellular redox
balance, control of oxidative stress, influencing apoptotic
signaling, and providing proper contractile properties
has been demonstrated [13, 14]. Moreover, although the
involvement of Nrf2 in DMD progression has been sug-
gested [15–18], the possible protective mechanisms were
not fully discovered. Therefore, we aimed to evaluate the
impact of Nrf2 transcriptional deficiency on the acute
muscle damage caused by CTX injection and chronic
injury using a murine model of DMD—mdx mice.
Methods
Animal models
All animal procedures and experiments were performed
in accordance with national and European legislation,
after approval by the 1st and 2nd Institutional Animal
Care and Use Committee (IACUC) in Kraków, Poland
(approval numbers: 66/2013, 199/2018, 148/2020). Mice
were kept in specific-pathogen-free (SPF) conditions
with water and food available ad libitum under con-
trolled temperature and humidity and 14 h/10 h (light/
dark) cycles.
Mdx mice (C57BL/10ScSn-Dmdmdx/J) and control
mice (C57BL/10ScSnJ, WT) were purchased from the
Jackson Laboratory. The mice with disrupted Nfe2l2
gene on C57Bl/6 J background, originally developed by
Prof. Yamamoto [19] were provided by Prof. Antonio
Cuadrado [20] and further demonstrated by us to be a
transcriptional knockout (Nrf2tKO) [21]. To generate
Nrf2tKOmdx mice (deficient for both dystrophin and
transcriptionally active Nrf2), homozygous Nrf2tKO male
mice were crossed with homozygous Dmdmdx/mdx female
mice to obtain Nrf2+/− Dmdmdx/+ female mice or Nrf2+/−
Dmdmdx/Y male mice, which were subsequently bred to-
gether to generate Nrf2tKOmdx mice at mixed back-
ground C57BL/10ScSn and C57BL/6 J.
Bronisz-Budzyńska et al. Skeletal Muscle           (2020) 10:35 Page 2 of 22
In the experiments, if not stated otherwise, 10-12-
week-old male littermates or age-matched mice from
generation F2 to F5 were used. Accordingly, the double
knockout animals lacking both dystrophin and Nrf2 ex-
pression (Nrf2tKODmdmdx/Y) were compared to their
mdx littermates (Nrf2+/+Dmdmdx/Y). Additionally, mdx
mice were analyzed vs. WT (Nrf2+/+Dmd+/Y) mice and
the comparison of Nrf2tKO (Nrf2tKODmd+/Y) mice vs.
WT mice was studied as well.
The generation of double knockouts was hence done
accordingly to other studies in which mdx mice were
crossed with relevant knockouts [9, 22–25]. Genotyping
of animals was performed by PCR on the DNA isolated
from the tails.
CTX-induced injury
Male and female C57BL/6 J (WT and Nrf2tKO) mice at
8-15 weeks of age were used for the myoinjury experi-
ment. Hind limbs of mice were shaved and gastrocne-
mius muscles (GM) were injected with 25 μl of 20 μmol/
l cardiotoxin from Mozambique spitting cobra (Naja
mossambica mossambica; Sigma-Aldrich), while control
mice were injected with saline. Animals were provided
with analgesia (50 μl, 0.03 mg/ml buprenorphine) after
injection and in the next 2 days. Mice were euthanized
on the 1st, 3rd, 7th, 14th, and 28th day after CTX injury.
Subsequently, plasma was taken and GM were harvested
for further analyses.
Treadmill test
To assess muscle functionality and performance, the tread-
mill test was performed as described previously [9, 24].
Additionally, to worsen the dystrophic phenotype, mice
were subjected to chronic treadmill exercises. The training
protocol started at the age of 4 weeks. After 3 days of
acclimatization, mice underwent a run on a horizontal
treadmill at 12m/min for 30min twice a week for 4 weeks,
according to published protocols [26, 27]. Experiments
were performed using the Exer-3/6 treadmill (Columbus
Instruments).
Forelimb grip strength test
Forelimb grip strength was assessed using a grip strength
meter (GSM) with a triangular pull bar (Ugo Basile) ac-
cording to the published protocol with modifications
[28]. Briefly, the animals were gently held by the tail
allowing them to grasp the grid using forelimbs. After-
ward, mice were moved horizontally toward the bar and
pulled back until the grip was released. The measure-
ments were repeated 5 times with a 1-min break in be-
tween. The results were calculated as an average from 5
measurements, normalized to body weight, and
expressed as N/kg BW.
Plasma creatine kinase and lactate dehydrogenase
measurement
Plasma was obtained by blood collection from vena cava
to heparin-coated tubes followed by centrifugation at
1000×g for 10 min at 4 °C just before the terminal pro-
cedure and collection of GM. The activity of CK and
LDH were measured using diagnostic Liquick Cor-CK
and Liquick Cor-LDH kit, respectively (P.Z. CORMAY)
following the manufacturer’s instruction using plasma
diluted 10 times for measurements.
Histological analysis
GM were dissected, immediately fixed in 10% formalin,
dehydrated, embedded in paraffin, and cut into 4 μm
sections. Subsequently, sections were deparaffinized,
rehydrated, and subjected to histological stainings.
Hematoxylin and eosin staining (H&E, Sigma-Aldrich)
was performed to visualize inflammation and regenerat-
ing myofibers according to standard protocols. For Mas-
son’s trichrome staining assessing collagen content
(fibrosis evaluation), sections were fixed overnight in
Bouin’s solution and sequentially treated with Biebrich
scarlet-acid fuchsin, phosphotungstic acid/phosphomo-
lybdic acid, and aniline blue (Sigma-Aldrich, according
to the vendor’s instructions). Inflammation, muscle dam-
age, fibrosis, and regeneration scoring was done by a
blinded experimenter using the following description of
arbitrary scale:
0—no signs of inflammation/collagen deposition/
regenerating fibers
1—any sign of inflammation, myofibre swelling/
collagen deposition/regenerating fibers
2—signs of inflammation, myofibre swelling, and
rhabdomyolysis/collagen deposition/regenerating fibers
are well visible and significant but occupy less than half
of the field of view
3—signs of inflammation, myofibre swelling, and
rhabdomyolysis/collagen deposition/regenerating fibers
take up more than half of the field of view
4—signs of inflammation, myofibre swelling, and
rhabdomyolysis/collagen deposition/regenerating fibers
take up all field of view
Immunohistofluorescent stainings
GM were harvested and snap-frozen in optimal cutting
temperature compound (OCT, Leica) in liquid nitrogen-
chilled isopentane and stored at −80 °C until processed.
Frozen tissues were cryosectioned (10 μm) using a cryo-
stat (Leica) and placed on glass slides coated previously
with poly-L-lysine (Sigma-Aldrich).
For evaluation of necrotic fibers (accumulating IgG
and IgM) and regenerating fibers (positive for embryonic
myosin chain, eMyHC), sections were blocked with 10%
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goat serum (Sigma-Aldrich), 5% bovine serum albumin
(BSA, BioShop), and mouse-on-mouse (M.O.M.TM, Vec-
tor Laboratories) for 1 h at room temperature, and incu-
bated with rat anti-mouse laminin α2 (1:500; 4H8-2,
Abcam) and mouse anti-mouse eMyHC (1:100, F1.652,
DSHB) primary antibodies for 1 h at 37 °C. After three
washes with PBS (5 min each), the sections were incu-
bated with goat anti-rat Alexa Fluor 568 (1:1000, A-
11077, Thermo Fisher Scientific) and goat anti-mouse
IgG/IgM/IgA Alexa Fluor 488 (1:50, A-10667, Thermo
Fisher Scientific) secondary antibodies for 1 h at 37 °C.
Paired-box 7 (Pax7) level was checked on frozen cryo-
sections fixed by 4% paraformaldehyde (Santa Cruz Bio-
technology) and cold methanol (Avantor Performance
Materials Poland S.A.). After antigen retrieval, samples
were blocked for 30 min with 2.5% BSA and for the next
30 min with M.O.M.TM. Following two washes with PBS,
sections were stained overnight at 4 °C with mouse anti-
mouse Pax7 (1:100, Pax7, DSHB) and rabbit anti-mouse
laminin α2 (1:1000, L9393, Sigma-Aldrich) primary anti-
bodies diluted in 0.1% BSA. Secondary stains were done
using goat anti-mouse Alexa Fluor 488 (1:500, A11008,
Thermo Fisher Scientific) and goat anti-rabbit Alexa
Fluor 568 (1:500, A-11077, Thermo Fisher Scientific)
antibodies diluted in 0.1% BSA. Finally, sections were
washed with PBS 3×5 min, during the last washing
step nuclei were stained with Hoechst 33258 (10 μg/
ml, Sigma-Aldrich) followed by mounting the slides
with fluorescence mounting medium (Dako). Images
were acquired using a fluorescent microscope (Leica
DMI6000B) and analyzed in the ImageJ software. The
number of necrotic or eMyHC-positive fibers was
counted in 8 fields of view or within all injured sites
of GM in the experiments with CTX injection, re-
spectively. The percentage of necrotic/eMyHC+ myofi-
bers was calculated in relation to the total number of
myofibers. The ratio of Pax7+ nuclei/myofiber was es-
timated by counting Pax7+ nuclei and myofibers in at
least 10 fields of view.
Gastrocnemius muscle cross-sectional area (CSA) and
the mean fiber area were determined by semi-automatic
muscle analysis using segmentation of histology (SMAS
H) [29] based on immunofluorescent staining of laminin
described above. Only the injured area of the muscle
was examined by the experimenter blinded to the mouse
genotype.
Gene expression analysis by quantitative real-time PCR
Harvested skeletal muscle tissues were stored in RNAla-
ter RNA Stabilization Solution (Invitrogen) at −80 °C
until processed. GM from 12-week-old mice were used
to isolate RNA by homogenization in 1 ml of Qiazol
Total RNA Isolation Reagent (Qiagen) using TissueLyser
(Qiagen), following the manufacturer’s instructions. The
concentration and quality of RNA were determined
spectrophotometrically (NanoDrop, Thermo Fisher Sci-
entific). To synthesize cDNA, the reverse transcription
reaction was performed on 1 μg RNA using RevertAid
reverse transcriptase (Thermo Fisher Scientific) or Mys-
tiCq® microRNA cDNA Synthesis Mix (Sigma-Aldrich).
qPCR was performed with Applied BiosystemsTM Ste-
pOnePlus Real-Time PCR (Thermo Fisher Scientific) in
a mixture containing cDNA, SYBR Green PCR Master
Mix (SYBR Green qPCR Kit, Sigma-Aldrich), forward
and reverse primers recognizing murine genes (Table 1),
and muscle-specific murine microRNAs (Table 2). A
universal reverse primer for miRNAs qPCR was supplied
by a vendor. The relative quantification of gene expres-
sion was quantified based on the comparative Ct
(threshold cycle value) method. Gene expression levels
were calculated by normalizing to the level of house-
keeping gene elongation factor 2 (Eef2) or constitutive
small nuclear RNA U6 in the case of microRNA.
Analysis of mononucleated cell populations in skeletal
muscles by flow cytometry
Samples for flow cytometry were prepared as described
previously [9, 10]. Briefly, mice were euthanized and
Table 1 Sequences of primers used for qPCR analysis
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perfused immediately with saline containing 0.5 U/ml
heparin through the left ventricle. Then, hind limbs mus-
cles were excised, weighted, minced, and digested at 37 °C
for 45min in a solution containing collagenase IV (5mg/
ml; Gibco; Invitrogen) and dispase (1.2 U/ml; Gibco; Invi-
trogen). Digested muscles were passed through 100 μm
cell strainer, washed with PBS, pelleted after centrifuga-
tion, and resuspended in PBS + 2% fetal bovine serum.
Subsequently, the number of cells per milliliter was calcu-
lated using the Bürker chamber. Samples were stained
with the following antibodies: rat anti-mouse CD45-APC-
eFluor780 (30-F11, eBioscience), rat anti-mouse CD31-PE
(MEC 13.3, BD Bioscience), rat anti-mouse CD34-Alexa
Fluor 700 (RAM 34, eBioscience), rat anti-mouse Ly6A/E-
PE-Cy7 (Sca-1; D7, eBioscience), rat anti-mouse α7-
integrin-PE (334908, R&D Systems)—to analyze muscle
SCs and fibro-adipogenic progenitors (FAPs). After fix-
ation and permeabilization, mouse anti-MyoD (G-1, Santa
Cruz Biotechnology) and rat anti-mouse Ki-67-FITC
(SolA15, eBioscience) were applied. Subsequently, to de-
tect MyoD, secondary goat anti-mouse Alexa Fluor 568
(Life Technologies) antibody was added. Rat anti-mouse
CD45-APC-eFluor780 (30-F11, eBioscience), rat anti-
mouse CD11b-Alexa Fluor 700 (M1/70, eBioscience), rat
anti-mouse F4/80-APC (BM8, eBioscience), rat anti-
mouse MHCII-PE-Cy7 (M5/114.15.2, BD Bioscience), rat
anti-mouse CD206-PerCP/Cy5.5 (C068C2, BioLegend),
rat anti-mouse Ly6C-AlexaFluor488 (HK 1.4, BD Biosci-
ences), and rat anti-mouse Ly6G-PE (1A8, BioLegend)
were used to analyze macrophages, whereas rat anti-
mouse CD45-APC-eFluor780 (30-F11, eBioscience), ham-
ster anti-mouse CD3e-PE-Cy7 (145-2C11, eBioscience),
mouse anti-mouse NK1.1-FITC (PK 136, BioLegend), rat
anti-mouse CD4-PerCP/Cy5.5 (RM 4-5, BD Biosciences),
and rat anti-mouse CD8a-Alexa Fluor 700 (53-6.7, BioLe-
gend)—to analyze lymphocyte populations and NK-cells.
Before flow cytometry analysis, all cells were additionally
stained with Hoechst 33342 (10 μg/ml). Data were ac-
quired with a Fortessa flow cytometer (BD Biosciences)
and analyzed using the FACSDiva software (BD Biosci-
ences). Gates were set based on the appropriate fluores-
cent minus one (FMO) controls. In the case of MyoD
staining, FMO controls were performed for each mouse
used in the experiment. Results are presented as a cell
number per milligram of tissue.
Protein isolation
Total protein was isolated from snap-frozen GM by
homogenization in lysis buffer—PBS containing inhibitors
of proteinases (Roche) and 1% Triton X-100 (BioShop)
using TissueLyser (Qiagen). Samples were then incubated
on ice for 30min, centrifuged (8000×g, 10min, 4 °C), su-
pernatants were collected and stored at −80 °C.
Protein analysis
To assess monocyte chemoattractant protein 1 (MCP-1)
and vascular endothelial growth factor A (VEGF) protein
level, GM lysates were subjected to LuminexTM measure-
ment according to the manufacturer’s instructions (Life
Technologies) whereas osteopontin concentration in
plasma was determined by ELISA following the vendor’s
protocol (R&D System). The results from MCP-1 and
VEGF measurement were calculated as pg/mg of total
protein and the level of osteopontin was shown in ng/ml.
Statistics
Data are presented as mean ± SEM and analyzed with
the unpaired two-tailed Student’s t test to determine dif-
ferences between two groups or one-way ANOVA
followed by Tukey’s post hoc test for multiple groups. p
≤ 0.05 was considered as significant. Grubb’s test was
used to identify significant outliers, GraphPad Prism for
graphs and statistical analyses.
Results
Lack of transcriptionally active Nrf2 enhances skeletal
muscle damage after CTX-induced injury
To analyze the effect of Nrf2 transcriptional deficiency
during acute muscle damage, we examined inflammatory
reaction and muscle degeneration as well as regeneration
in the model of CTX-induced myoinjury. The level of
muscle damage and inflammatory infiltration evaluated
based on H&E staining (Fig. 1a, b) was significantly
higher in Nrf2tKO mice on the 3rd day after muscle dam-
age. Although the activity of CK (Fig. 1c) was increased
in Nrf2tKO animals on day 1 after injection, a statistically
significant difference between WT and Nrf2tKO mice
was not evident. On the other hand, the level of LDH
(Fig. 1d) was significantly elevated in mice of both geno-
types, and additionally, it was much higher in Nrf2tKO
animals in comparison to WT on the 1st day after CTX
injection. Moreover, we have shown increased protein
level of pro-inflammatory cytokine MCP-1 (Fig. 1e) and
mRNA level of Hmox1 (Fig. 1f), Il1b (Fig. 1g) and Il6
(Fig. 1h) on the 1st day after CTX injection in both ge-
notypes. Furthermore, IHF analysis of necrotic fibers on
the 3rd day after myoinjury did not reveal differences
between genotypes (Fig. 1i, j).
Table 2 Sequences of primers used for miRNA-specific qPCR
analysis
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Fig. 1 CTX-induced injury in GM of WT and Nrf2tKO animals. (a) Representative photos and (b) semi-quantitative assessment of GM damage
based on H&E staining; n = 4-6. The activity of (c) CK and (d) LDH in plasma; activity assay; n = 4-5. (e) MCP-1 protein level in GM, LuminexTM;
n = 4-5. (f) Hmox1, (g) Il1b, (h) Il6 level in GM; qRT-PCR; n = 4-6. (i) Representative photos of microscopic assessment of myofiber necrosis in GM
and (j) quantification of the staining; n = 4. The data are presented as mean +/− SEM; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 vs. day
0; #p ≤ 0.05; ###p ≤ 0.001 vs. WT, one-way ANOVA with Tukey’s post hoc test. The scale bars represent 100 μm
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Muscle regeneration is not affected in the absence of
transcriptionally active Nrf2 following CTX-induced injury
To assess the role of Nrf2 during muscle regeneration fol-
lowing the acute muscle injury caused by CTX injection, we
examined the mRNA level of Myh3 and the number of
eMyHC+ myofibers. Following muscle damage, we observed
a higher level of Myh3 in both WT and Nrf2tKO animals on
the 7th day after injury, however, there were no differences
among genotypes in all analyzed timepoints (Fig. 2a).
Accordingly, the number of eMyHC+ fibers (Fig. 2b, c), CSA
Fig. 2 Muscle regeneration in GM of WT and Nrf2tKO animals after CTX-induced injury. (a) Myh3 level in GM; qRT-PCR; n = 4-6. (b) Representative
photos of immunofluorescent staining for eMyHC and (c) quantification of the percentage of eMyHC positive myofibers; n = 5. (d) Cross sectional
area of fibers 7 days after CTX; n = 3-4. (e) Mean fiber area 7 days after CTX; n = 3-4. The data are presented as mean +/− SEM; ***p ≤ 0.001 vs.
day 0, one-way ANOVA with Tukey’s post hoc test. The scale bars represent 100 μm
Fig. 3 General phenotype of non-exercised WT, Nrf2tKO, mdx, and Nrf2tKOmdx mice. (a) Muscle performance; downhill running treadmill test; n =
5-9. (b) Body weight of mice; n = 14-26; (c) Gastrocnemius muscle mass; n = 4-18. The data are presented as mean +/− SEM; **p ≤ 0.01, one-way
ANOVA with Tukey’s post hoc test
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(Fig. 2d), and mean fiber area (Fig. 2e) were similar on day 7
after injury.
Transcriptional deficiency of Nrf2 does not aggravate
dystrophic phenotype in mdx mice
To investigate the role of Nrf2 in chronic muscle injury,
we generated dystrophic mice lacking the transcriptional
activity of Nrf2 (Nrf2tKOmdx). In order to determine
whether the lack of Nrf2 can affect exercise perform-
ance, mice were subjected to a downhill treadmill run
to exhaustion. As shown by us [9] and others [24]
previously, and confirmed in the present study, mdx
mice were able to run a shorter distance than WT
(Fig. 3a). However, we did not observe an effect of
the transcriptional deficiency of Nrf2 on the running
pattern. The exercise capacity of Nrf2tKO animals was
comparable to WT mice and Nrf2tKOmdx mice run
similar distance as mdx counterparts (Fig. 3a). Body
weight (Fig. 3b) and GM mass (Fig. 3c) were signifi-
cantly increased in mdx mice in comparison to
healthy animals, while in Nrf2tKOmdx, no striking dif-
ferences compared with age-matched mdx mice were
found.
Transcriptional knockout of Nrf2 does not exacerbate
muscle degeneration in non-exercised mdx mice
Muscle degeneration was evaluated based on the per-
centage of necrotic fibers in GM as well as the plasma
level of CK and LDH, typical markers of muscle damage.
Neither the number of necrotic fibers (Fig. 4a, b) nor
LDH (Fig. 4c) and CK (Fig. 4d) activity was changed be-
tween dystrophic mice additionally lacking Nrf2 and
mdx animals, indicating a comparable level of muscle in-
jury. As suspected, plasma LDH and CK levels of mdx
mice were elevated compared with those of WT mice
(Fig. 4c, d, respectively).
Lack of Nrf2 transcriptional activity does not aggravate
the inflammatory reaction in non-exercised dystrophic
skeletal muscles
Since Nrf2 has been reported as a master regulator of
anti-oxidative responses that contributes to the anti-
inflammatory process [30, 31], we have assessed whether
it can affect the inflammatory reaction in skeletal muscle
in our experimental conditions. Analysis of H&E stain-
ing demonstrated that mdx mice lacking transcriptional
activity of Nrf2 had a similar inflammation score to mdx
Fig. 4 Muscle degeneration of non-exercised WT, Nrf2tKO, mdx, and Nrf2tKOmdx mice. (a) Microscopic assessment of myofiber necrosis in GM
using immunofluorescent staining of IgM and IgG (green) binding and (b) its calculation; n = 7-9. The activity of (c) LDH and (d) CK in plasma;
activity assay; n = 3-6. The data are presented as mean +/− SEM; *p ≤ 0.05, one-way ANOVA with Tukey’s post hoc test; ##p ≤ 0.01 Student’s t
test. The scale bars represent 100 μm
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Fig. 5 (See legend on next page.)
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mice in both GM (Fig. 5a, b) and diaphragm (Fig. 5c, d).
Moreover, the expression of Hmox1, an anti-
inflammatory factor shown by us to be upregulated in
dystrophic muscles [9], was again potently elevated in
GM of mdx mice. However, it was the same in
Nrf2tKOmdx mice, indicating that Nrf2 transcriptional
activity is dispensable for Hmox1 induction in the
muscles (Fig. 5e).
To shed more light on the inflammatory status, we
have performed a comprehensive analysis of different
leukocyte populations within hind limb muscles using
flow cytometry. Mdx mice demonstrated an abundance
of macrophages defined as CD45+F4/80+CD11b+ cells.
However, no further changes in the infiltration of this
population into skeletal muscle were caused by Nrf2
transcriptional deficiency (Fig. 5 f, g). Due to the diverse
functions of different subpopulations of macrophages
[4], in the next step, we have investigated M1-like and
M2-like macrophages, based on the gating strategy dis-
criminating between MHCII and CD206 expression by
CD45+F4/80+CD11b+ cells. The subsets of both M1-like
(CD45+F4/80+CD11b+MHCIIhiCD206low) and M2-like
(CD45+F4/80+CD11b+MHCIIlow CD206hi) macrophages
were much more elevated in dystrophic mice in com-
parison to WT but the lack of transcriptionally active
Nrf2 did not further change their number (Fig. 5h, i, j).
The number of NK cells (CD45+SSClowCD3−NK1.1+)
was significantly higher in mdx mice in comparison to
(See figure on previous page.)
Fig. 5 Infiltration of non-exercised WT, Nrf2tKO, mdx, and Nrf2tKOmdx hind limb muscle and diaphragm with leukocytes and macrophages. (a)
Representative photos and (b) semi-quantitative analysis of inflammation in GM based on H&E staining; n = 4-6. (c) Representative photos and (d)
semi-quantitative analysis of inflammation in diaphragm based on H&E staining; n = 4-6. (e) Hmox1 level in GM; qRT-PCR; n = 8-11. (f) Number of
macrophages (CD45+F4/80+CD11b+); flow cytometry; n = 5; (g) representative two-parameters flow cytometry dot plots. (h) Number of M1-like
macrophages (CD45+F4/80+CD11b+MHCIIhiCD206lo) and (i) M2-like macrophages (CD45+F4/80+CD11b+MHCIIloCD206hi); flow cytometry; n = 5; (j)
representative two-parameters flow cytometry dot plots. The data are presented as mean +/− SEM; **p ≤ 0.01; ***p ≤ 0.001, one-way ANOVA
with Tukey’s post hoc test. The scale bars represent 100 μm
Fig. 6 Infiltration of non-exercised WT, Nrf2tKO, mdx, and Nrf2tKOmdx hind limb muscle with NK cells and lymphocytes. (a) Number of NK cells
(CD45+SSClowCD3−NK1.1+) and (b) lymphocytes T (CD45+SSClowCD3+); flow cytometry; (c) representative two-parameters flow cytometry dot
plots. (d) Number of lymphocytes Th (CD45
+SSClowCD3+CD4+CD8−) and (e) Tc (CD45
+SSClowCD3+CD4−CD8+); flow cytometry; (f) representative
two-parameters flow cytometry dot plots. The data are presented as mean +/− SEM; n = 5; ***p ≤ 0.001; ****p ≤ 0.0001, one-way ANOVA with
Tukey’s post test
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WT. Conversely, dystrophic mice additionally lacking
Nrf2 transcriptional activity exhibited decreased NK
number reaching a similar number to the one observed
in WT animals (Fig. 6a, c). The number of lymphocytes
T (CD45+SSClowCD3+) (Fig. 6b, c), T helper (Th;
CD45+SSClowCD3+CD4+CD8−) (Fig. 6d, f), and T cyto-
toxic (Tc; CD45
+SSClowCD3+CD4−CD8+) (Fig. 6e, f)
were the same among all four genotypes.
The role of Nrf2 transcriptional deficiency on muscle
fibrosis in non-exercised mdx mice
We have found that transforming growth factor beta-1
(Tgfb1) and collagen type I alpha 1 (Col1a1) were upreg-
ulated in mdx vs. WT animals and were further elevated
in mdx mice lacking additionally transcriptionally active
Nrf2 (Fig. 7a, b), suggesting that the transcriptional defi-
ciency of Nrf2 could enhance fibrosis. To confirm those
results, a histological analysis of collagen deposition
based on Masson’s trichrome staining was performed.
Accordingly, endomysial collagen content was signifi-
cantly elevated in both GM (Fig. 7c, d) and diaphragm
(Fig. 7e, f) of dystrophic mice; however, it was not fur-
ther exacerbated in mdx mice lacking transcriptionally
active Nrf2. Moreover, as FAPs are also involved in the
progression of DMD [32], we checked their numbers
using flow cytometry. Our results showed that FAPs, de-
fined as CD45−CD31−Sca1+a7i−CD34+ cells, were upreg-
ulated by dystrophin deficiency, but their numbers were
not further affected by the lack of transcriptionally active
Nrf2 (Fig. 7g, h).
A decrease in the expression of angiogenic mediators in
non-exercised mdx mice is not affected by the lack of
transcriptionally active Nrf2
Dysregulation of angiogenesis may greatly contribute to
DMD progression [33]. Moreover, Nrf2 was shown to
regulate neovascularization and to exert a pivotal role in
angiogenic signal transduction and angiogenic potential
of not only endothelial cells itself but also bone marrow-
derived proangiogenic cells [34]. Therefore, we aimed to
investigate the angiogenic signaling in our model. Firstly,
we have checked the mRNA and protein level of the
major proangiogenic factor, VEGF, in GM of mice of all
genotypes. The mRNA expression was diminished in
mdx mice but no further changes were observed in
double knockouts (Fig. 8a). Concomitantly, the level of
VEGF protein was potently downregulated in dystrophic
GM; however, the lack of transcriptionally active Nrf2
did not affect this production in both healthy and dys-
trophic mice (Fig. 8b). A similar trend of changes was
found when the expression of Kdr, a receptor for VEGF
was evaluated (Fig. 8c).
Nrf2 transcriptional deficiency does not affect the
number and proliferation of muscle SCs but it may
influence muscle regeneration in non-exercised
dystrophic animals
The number of SCs evaluated based on IHF staining and
calculation of the ratio of Pax7-positive nuclei to myofi-
bers revealed an increased number of Pax7+ cells in
dystrophin-deficient mice in comparison to healthy ones,
however, the additional effect of the lack of transcrip-
tionally active Nrf2 was not observed (Fig. 9a, b). Fur-
thermore, flow cytometry analysis demonstrated a
considerable increase in the number of MyoD-positive
SCs (CD45-CD31−Sca1−α7integrin+MyoD+) in mdx
mice, but it was not further changed by Nrf2 transcrip-
tional deficiency (Fig. 9c). We have also checked the
proliferation of MyoD-positive SCs by cytofluorimetric
analysis of cells expressing Ki67. Significantly enhanced
proliferation of MyoD+ SCs in dystrophic mice com-
pared to healthy animals was observed. This was not fur-
ther potentiated in Nrf2tKOmdx mice (Fig. 9d, e).
Although there was no effect of the lack of transcrip-
tionally active Nrf2 on the number and proliferation of
SCs, we have shown that the regeneration process is af-
fected in the course of chronic injury in dystrophic mice,
and what is more—it is additionally altered by the Nrf2
status. Accordingly, dystrophic mice showed higher ex-
pression of myogenic regulatory factors such as myo-
genic differentiation 1 (Myod1) and myogenin (Myog)
than their healthy counterparts, and the expression of
those factors was further enhanced by Nrf2 transcrip-
tional deficiency (Fig. 10a, b).
Additionally, we have checked the mRNA level of
muscle-specific microRNAs which also contribute to the
process of muscle regeneration [35]. Expression of miR-
206 (Fig. 10c) was elevated in mdx mice in comparison
to age-matched WT animals whereas miR-1 (Fig. 10d)
and miR-133a/b (Fig. 10e) showed the opposite pattern.
However, none of them were affected by Nrf2 transcrip-
tional deficiency.
Finally, the number of myofibers expressing eMyHC, the
marker of regeneration, was diminished in mdx mice add-
itionally lacking transcriptionally active Nrf2 in comparison
tomdx counterparts (Fig. 10f, g). However, histological ana-
lysis of centrally nucleated fibers did not show differences
between mdx and Nrf2tKOmdx animals (Fig. 10h, i).
Chronic treadmill exercise aggravates skeletal muscle
degeneration and inflammation in dystrophic animals
lacking transcriptional activity of Nrf2
In order to identify the role of Nrf2 under aggravated
dystrophic conditions, we have analyzed muscle func-
tionality, degeneration, and inflammation after 4 weeks
of chronic treadmill exercises. Firstly, reduced muscle
function measured by the grip strength test in mdx mice
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Fig. 7 Fibrosis in non-exercised WT, Nrf2tKO, mdx, and Nrf2tKOmdx hind limb muscles and diaphragm. (a) Tgfb1, (b) Col1a1 levels in GM; qRT-PCR;
n = 9-11. (c) Representative photos and (d) semi-quantitative analysis of collagen deposition in GM based on Masson’s trichome staining; n = 3-5.
(e) Representative photos and (f) semi-quantitative analysis of collagen deposition in diaphragm based on Masson’s trichome staining; n = 5-8.
(g) Number of FAPs (CD45+CD31−Sca1+a7i−CD34+); flow cytometry; n = 5; (h) representative two-parameters flow cytometry dot plots. The data
are presented as mean +/− SEM; *p ≤ 0.05; ***p ≤ 0.001; ****p ≤ 0.0001, one-way ANOVA with Tukey’s post hoc test. The scale bars
represent 100 μm
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in comparison to healthy counterparts was shown; how-
ever, it was not additionally altered by the transcriptional
deficiency of Nrf2 (Fig. 11a). Moreover, the activity of
LDH and CK in plasma did not differ in Nrf2tKOmdx vs.
mdx animals (Fig. 11b, c, respectively).
The number of necrotic fibers (Fig. 11d, e) was signifi-
cantly higher in GM of mdx mice in comparison to WT,
and interestingly, it was further increased in Nrf2tKOmdx
animals in comparison to mdx (Fig. 11d, e). However,
this was not observed in the diaphragm (Fig. 11f, g). Fur-
thermore, the same pattern was noticed in the case of
inflammatory infiltration evaluated through H&E stain-
ing—higher inflammatory extent in Nrf2tKOmdx animals
in comparison to mdx in GM (Fig. 11h, i), but not in the
diaphragm (Fig. 11j, k).
As muscle fibrosis might be enhanced by chronic
treadmill exercises [36], we have checked if it is altered
by an additional lack of Nrf2. Collagen deposition ana-
lysis based on Masson’s trichrome staining revealed in-
creased collagen content in mdx mice; however, it was not
further altered by the transcriptional deficiency of Nrf2,
neither in GM (Fig. 12a, b) nor the diaphragm (Fig. 12c,
d). Moreover, the plasma level of osteopontin, a biomarker
of DMD associated with fibrosis [37], was comparable be-
tween mdx and Nrf2tKOmdx mice (Fig. S1 A).
Inflammation and fibrosis are not affected in 24-week-old
dystrophic mice by the lack of transcriptional activity of
Nrf2
To assess the role of Nrf2 transcriptional deficiency
on inflammation and fibrosis processes in old mice,
we have performed H&E and Masson’s trichrome
staining on GM and diaphragm of 24-week-old ani-
mals. We have observed increased inflammatory infil-
tration based on H&E staining in both gastrocnemius
(Fig. 13a, b) and diaphragm (Fig. 13c, d) muscles in
mdx mice in comparison to their healthy counter-
parts; however, it was not further changed by the lack
of transcriptionally active Nrf2. Similarly, the same
trend was observed in the case of fibrosis content,
and analyzed based on Masson’s trichrome staining.
Increased collagen deposition in GM (Fig. 13e, f) and
diaphragm (Fig. 13g, h) of dystrophic mice was dem-
onstrated, but it was not altered by the lack of Nrf2
transcriptional activity in both muscles.
Discussion
DMD is still an incurable disease with very limited treat-
ment possibilities, including corticosteroids [38]. How-
ever, despite having a beneficial effect on muscle
function, these drugs cause many side effects [39].
Therefore, identifying new targets for anti-inflammatory
treatment may contribute to the development of novel
therapeutic strategies. Taking into consideration the
pleiotropic activity of Nrf2, which drives the expression
of anti-inflammatory, anti-oxidant, and cytoprotective
genes, we aimed to investigate its role in the acute
muscle injury induced by CTX injection and in the pro-
gression of DMD using two different mouse models—
mdx and exacerbated dystrophic phenotype—mdx mice
subjected to the long-term treadmill exercise. In our
study, we found that the absence of transcriptionally ac-
tive Nrf2 may be associated with increased muscle dam-
age after acute muscle injury following CTX injection
and under aggravated dystrophic conditions, however, it
did not significantly affect the pathophysiological hall-
marks of DMD progression.
Due to the disruption of the DGC complex and in-
creased sarcolemmal permeability in DMD [40], serum
proteins such as IgG and IgM, which are typically found
only in circulation, are accumulated in damaged, nec-
rotic myofibers [41]. We have shown that the number of
such necrotic fibers does not differ between non-
exercised mdx and Nrf2tKOmdx mice. Although we have
demonstrated higher levels of CK and LDH in the serum
of non-exercised mdx mice in comparison to healthy
counterparts, their levels were not further elevated in
Fig. 8 Expression of angiogenic mediators in skeletal muscle of non-exercised WT, Nrf2tKO, mdx, and Nrf2tKOmdx mice. The expression of (a) Vegfa
in GM; qRT-PCR; n = 6-10 and (b) VEGF protein level in GM, LuminexTM; n = 6-7. (c) The expression of VEGF receptor (Kdr); qRT-PCR; n = 6-10. The
data are presented as mean ± SEM. *p ≤ 0.05; **p ≤ 0.01, one-way ANOVA with Tukey’s post hoc test
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dystrophic mice lacking transcriptionally active Nrf2.
We have also performed such analysis after a single
CTX injury, a model where the kinetics of degeneration
and inflammation processes are more stable than during
DMD development. Although a similar experimental
model was previously utilized by Shelar et al. [42], the
degeneration has not been checked. In our hand, Nrf2
transcriptional deficiency was associated with the aggra-
vation of LDH activity in plasma on 1st day after injury
and enhanced muscle damage on 3rd day following CTX
injury. Hence, it might be hypothesized that at the stage
of massive macrophages infiltration after CTX injury oc-
curring just on day 3 [43], the lack of Nrf2 manifests
more profoundly, impairing the proper inflammatory re-
sponse. However, this hypothesis would require further
verification.
Inflammation is one of the most prominent features of
dystrophic muscles. In our studies, contrary to the ex-
pectations, inflammation was not exacerbated in dys-
trophic muscles lacking transcriptionally active Nrf2
both when total inflammatory extent was evaluated on
histological sections and by detailed analysis of immune
Fig. 9 Number and proliferation of SCs from non-exercised WT, Nrf2tKO, mdx, and Nrf2tKOmdx hind limb muscles. (a) Pax7 staining in GM;
representative photos. (b) Quantification of the ratio of Pax7+ cells per myofibre; n = 3-5. (c) Number of MyoD+ SCs
(CD45−CD31−Sca1−α7integrin+MyoD+); flow cytometry; n = 4-5. (d) Number of proliferating MyoD+ SCs
(CD45−CD31−Sca1−α7integrin+MyoD+Ki67+); flow cytometry; n = 5; (e) representative two-parameters flow cytometry dot plots. The data are
presented as mean +/− SEM; *p ≤ 0.05; one-way ANOVA with Tukey’s post hoc test. The scale bars represent 100 μm
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Fig. 10 Regeneration of GM of non-exercised WT, Nrf2tKO, mdx, and Nrf2tKOmdx mice. (a) Myod1, (b) Myog, (c) miR-206, (d) miR-1, (e) miR-133a/b
level in GM; qRT-PCR; n = 9-11. (f) Representative photos of immunofluorescent staining for eMyHC and (g) quantification of the percentage of
eMyHC positive myofibers; n = 5-7. (h) Representative photos and (i) semi-quantitative analysis of centrally nucleated myofibers in GM based on
H&E staining; n = 3-6. The data are presented as mean +/− SEM; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001, one-way ANOVA with Tukey’s
post hoc test; #p ≤ 0.05 Student’s t test. The scale bars represent 100 μm
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Fig. 11 (See legend on next page.)
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subtypes by flow cytometry. Of note, despite the fact Th
and Tc lymphocytes contribute to the pathogenesis of
DMD [6] and their functions may be regulated by Nrf2
[44], their numbers were changed neither by dystrophin
nor Nrf2 deficiency in non-exercised animals. An interest-
ing finding of our study is related to the NK cells’ abun-
dance—their number was significantly decreased in
Nrf2tKOmdx mice in comparison to mdx, in which they
are elevated in the muscles [45]. Hence, our observations
are consistent with previous reports showing an increased
percentage of NK cells following activation of Nrf2 [46].
Petrillo et al. demonstrated a higher expression of
Nrf2 and its target, HO-1, in muscle biopsies from DMD
patients in comparison to healthy individuals [15]. In
our model, we observed an elevated level of HO-1 in the
CTX-injured muscles on day 1 after injection, as well as
in the dystrophic, non-exercised mice, consistent with
our previous results [9, 10]. However, the effect of Nrf2
deficiency on the level of this important inflammatory
mediator has been noticed neither in Nrf2tKO following
CTX injury nor in non-exercised Nrf2tKOmdx indicating
that HO-1 may be regulated independently of Nrf2. In-
deed, such an Nrf2-independent regulation of HO-1,
relying on, e.g., Foxo1 transcription factor, has been
demonstrated in the muscles and SCs [9, 47].
Concomitantly, we have revealed that Nrf2 plays a dis-
pensable role in endomysial fibrosis in dystrophic mus-
cles, the process of accumulation of connective tissue,
which is the characteristic attribute of DMD pathology
[4], is associated with poor outcome [48] and linked
to the increased expression of TGF-β1 and collagen
[49–51]. We have observed elevated mRNA level of Tgfb1
Fig. 12 Fibrosis in WT, Nrf2tKO, mdx, and Nrf2tKOmdx hind limb muscle and diaphragm after the long-term treadmill. (a) Representative photos
and (b) semi-quantitative analysis of collagen deposition in GM based on Masson’s trichome staining; n = 6-8. (c) Representative photos and (d)
semi-quantitative analysis of collagen deposition in diaphragm based on Masson’s trichome staining; n = 6-8. The data are presented as mean
+/− SEM **p ≤ 0.01; ****p ≤ 0.0001, one-way ANOVA with Tukey’s post hoc test; the scale bars represent 100 μm
(See figure on previous page.)
Fig. 11 Muscle degeneration and inflammation of WT, Nrf2tKO, mdx, and Nrf2tKOmdx mice after the long-term treadmill. (a) Grip strength test; n =
6-8. The activity of (b) LDH and (c) CK in plasma; activity assay; n = 6-8. (d) Microscopic assessment of myofiber necrosis in GM using
immunofluorescent staining of IgM and IgG (green) binding and (e) its calculation; n = 6-8. (f) Microscopic assessment of myofiber necrosis in
diaphragm using immunofluorescent staining of IgM and IgG (green) binding and (g) its calculation; n = 6-8. (h) Representative photos and (i)
semi-quantitative analysis of inflammation in GM based on H&E staining; n = 6-8. (j) Representative photos and (k) semi-quantitative analysis of
inflammation in diaphragm based on H&E staining; n = 6-8. The data are presented as mean +/− SEM; *p ≤ 0.05, **p ≤ 0.01; ***p ≤ 0.001, ****p ≤
0.0001, one-way ANOVA with Tukey’s post hoc test; ##p ≤ 0.01 Student’s t test. The scale bars represent 100 μm
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Fig. 13 Inflammation and fibrosis in muscles of non-exercised 24-week-old WT, Nrf2tKO, mdx, and Nrf2tKOmdx mice. (a) Representative photos and
(b) semi-quantitative analysis of inflammation in GM based on H&E staining; n = 4-6. (c) Representative photos and (d) semi-quantitative analysis
of inflammation in diaphragm based on H&E staining; n = 5. (e) Representative photos and (f) semi-quantitative analysis of collagen deposition in
GM based on Masson’s trichome staining; n = 5. (g) Representative photos and (h) semi-quantitative analysis of inflammation in diaphragm based
on Masson’s trichome staining; n = 5-7. The data are presented as mean +/− SEM; ***p ≤ 0.001; ****p ≤ 0.0001, one-way ANOVA with Tukey’s
post hoc test; the scale bars represent 100 μm
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and Col1a1 not only in non-exercised mdx animals but
even at a higher degree in dystrophic mice additionally
lacking transcriptionally active Nrf2, what is consistent
with studies showing that Nrf2 acts as a protective agent
against fibrosis [52–54]. However, although the lack of
transcriptional activity of Nrf2 in dystrophic mice affected
mRNA of fibrotic genes, it was not reflected in the colla-
gen deposition in muscle’s histological sections. Moreover,
the number of FAPs remained comparable between those
two groups of animals. The observed differences may be
caused by the fact that the mRNA level points to a par-
ticular time-point, whereas collagen deposition showed
changes arising during disease progression.
Additionally, to fully understand the potential role of
Nrf2 in DMD progression, we have studied the inflam-
mation and fibrosis in older—24-week-old animals. Ac-
cordingly, differences between non-exercised mdx and
Nrf2tKOmdx were observed neither in GM nor in the
diaphragm. Importantly, our data are in line with the
work by Takemoto et al. [55] what might indicate that
older mdx mice are not a good model to study DMD
progression due to disease stabilization at later stages
[56–58]. Therefore, we have also looked at the role of
Nrf2 in exacerbated dystrophic phenotype—mice sub-
jected to long-term treadmill exercises. Interestingly, we
have observed an increased number of necrotic fibers in
GM of dystrophic mice in comparison to the diaphragm
what is in line with the previous findings [59]. However,
again, we did not find any changes in dystrophic muscle
functionality and other pathological aspects of DMD
driven by the lack of Nrf2 transcriptional activity except
for the higher level of degeneration and inflammation in
GM of Nrf2tKOmdx mice, but not in the diaphragm. The
latter could be explained by the applied experimental
protocol of chronic exercises with relatively low speed
and maintaining horizontal orientation, which possibly
did not influence the diaphragm, contrary to the applica-
tion of more acute protocols [60].
Effective muscle regeneration is achieved by SCs [61].
In DMD, repeated cycles of muscle damage and regener-
ation disturbed the balance between self-renewal and
differentiation, leading to premature depletion of the
SCs pool [62]. We have shown that the absolute number
of Pax7-positive SCs, as well as MyoD-positive SCs, was
notably increased in dystrophic animals as in the previ-
ous studies performed on mdx mice [63]. Nevertheless,
regardless of the method used, the number, as well as
the proliferation of dystrophic SCs, was not additionally
altered by Nrf2 transcriptional deficiency. It is well
established that muscle regeneration is controlled by
myogenic regulatory factors (MRFs) such as MyoD and
myogenin. Their elevated level was observed by us in
mdx mice and was further upregulated by additional
Nrf2 transcriptional deficiency, the mechanism of which
is currently investigated. Newly formed myofibers are
characterized by the expression of unique myosin iso-
forms such as eMyHC. The number of eMyHC-positive
myofibers was lower in mdx mice additionally lacking
transcriptional activity of Nrf2 in comparison to mdx.
However, because there are many repeated cycles of
muscle damage and regeneration in DMD, it is difficult
to conclude how Nrf2 affects this process based on tran-
siently expressed eMyHC [64]. Therefore, we also
checked muscle regeneration after acute muscle injury in-
duced by CTX injection, a method that allows studying
muscle regeneration in more controlled and reproducible
conditions [65]. In the model of CTX-induced muscle in-
jury, no effect of the lack of Nrf2 transcriptional deficiency
was observed. This finding is consistent with previous
studies where a similar level of regeneration in transcrip-
tionally deficient Nrf2 and control mice was demonstrated
[55]. Contrary, Shelar et al. presented delayed regeneration
of tibialis anterior muscle in Nrf2-deficient mice [42],
however, a few experimental differences (e.g., the age of
animals and divergent muscles injected with various doses
and types of CTX) may potentially explain discrepancies
in the results obtained in both studies.
Overall, our results did not show the prominent effects
of Nrf2 deficiency both in acute and in chronic muscle
injury. However, it is still possible that beneficial effects
could be observed through Nrf2 induction or overex-
pression. Sun et al. have shown that dystrophic pheno-
type may be markedly alleviated in mdx mice by
treatment with sulforaphane (SFN) [16, 18], an isothio-
cyanate that activates Nrf2 by modifying Keap1 cysteines
[66]. Moreover, several studies have outlined that some
features of DMD might be improved by other anti-
oxidant compounds like resveratrol [67] or curcumin
[68], but their effect was not as strong as SFN [16, 18].
However, it is important to remember that such com-
pounds might work not solely through activation of
Nrf2, but they may also involve other mechanisms
[69–71], and in the above studies the involvement of
the Nrf2 pathway was not investigated in details.
Conclusion
Lack of transcriptionally active Nrf2 is associated with
slightly increased muscle damage after acute muscle injury
caused by CTX injection as well as degeneration and inflam-
matory infiltration of the gastrocnemius muscle in dystrophic
mice upon chronic treadmill exercises. Nevertheless, Nrf2
ablation does not significantly aggravate the most deleterious
pathological events such as degeneration, inflammation,
angiogenesis, and fibrotic scar formation as well as the
number and proliferation of SCs in the non-exercised mdx
mice model. Therefore, we conclude that the deficiency of
Nrf2 transcriptional activity has no profound impact on
muscle pathology in various models of muscle injury.
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SEM ***p≤0.001, one-way ANOVA with Tukey’s post-hoc test.
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